Jakinibs for the treatment of immune dysregulation in patients with gain-of-function signal transducer and activator of transcription 1 (STAT1) or STAT3 mutations.
Publication
, Journal Article
Forbes, LR; Vogel, TP; Cooper, MA; Castro-Wagner, J; Schussler, E; Weinacht, KG; Plant, AS; Su, HC; Allenspach, EJ; Slatter, M; Abinun, M ...
Published in: J Allergy Clin Immunol
November 2018
Treatment of the autoimmune and immune-dysregulatory features of patients with STAT1 GOF or STAT3 GOF disease remains challenging. Jakinibs have been used to treat the severe immune-dysregulation in patients with either STAT1 GOF or STAT3 GOF mutations.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
J Allergy Clin Immunol
DOI
EISSN
1097-6825
Publication Date
November 2018
Volume
142
Issue
5
Start / End Page
1665 / 1669
Location
United States
Related Subject Headings
- Treatment Outcome
- STAT3 Transcription Factor
- STAT1 Transcription Factor
- Pyrroles
- Pyrimidines
- Pyrazoles
- Protein Kinase Inhibitors
- Piperidines
- Nitriles
- Male
Citation
APA
Chicago
ICMJE
MLA
NLM
Forbes, L. R., Vogel, T. P., Cooper, M. A., Castro-Wagner, J., Schussler, E., Weinacht, K. G., … Leiding, J. W. (2018). Jakinibs for the treatment of immune dysregulation in patients with gain-of-function signal transducer and activator of transcription 1 (STAT1) or STAT3 mutations. J Allergy Clin Immunol, 142(5), 1665–1669. https://doi.org/10.1016/j.jaci.2018.07.020
Forbes, Lisa R., Tiphanie P. Vogel, Megan A. Cooper, Johana Castro-Wagner, Edith Schussler, Katja G. Weinacht, Ashley S. Plant, et al. “Jakinibs for the treatment of immune dysregulation in patients with gain-of-function signal transducer and activator of transcription 1 (STAT1) or STAT3 mutations.” J Allergy Clin Immunol 142, no. 5 (November 2018): 1665–69. https://doi.org/10.1016/j.jaci.2018.07.020.
Forbes LR, Vogel TP, Cooper MA, Castro-Wagner J, Schussler E, Weinacht KG, et al. Jakinibs for the treatment of immune dysregulation in patients with gain-of-function signal transducer and activator of transcription 1 (STAT1) or STAT3 mutations. J Allergy Clin Immunol. 2018 Nov;142(5):1665–9.
Forbes, Lisa R., et al. “Jakinibs for the treatment of immune dysregulation in patients with gain-of-function signal transducer and activator of transcription 1 (STAT1) or STAT3 mutations.” J Allergy Clin Immunol, vol. 142, no. 5, Nov. 2018, pp. 1665–69. Pubmed, doi:10.1016/j.jaci.2018.07.020.
Forbes LR, Vogel TP, Cooper MA, Castro-Wagner J, Schussler E, Weinacht KG, Plant AS, Su HC, Allenspach EJ, Slatter M, Abinun M, Lilic D, Cunningham-Rundles C, Eckstein O, Olbrich P, Guillerman RP, Patel NC, Demirdag YY, Zerbe C, Freeman AF, Holland SM, Szabolcs P, Gennery A, Torgerson TR, Milner JD, Leiding JW. Jakinibs for the treatment of immune dysregulation in patients with gain-of-function signal transducer and activator of transcription 1 (STAT1) or STAT3 mutations. J Allergy Clin Immunol. 2018 Nov;142(5):1665–1669.
Published In
J Allergy Clin Immunol
DOI
EISSN
1097-6825
Publication Date
November 2018
Volume
142
Issue
5
Start / End Page
1665 / 1669
Location
United States
Related Subject Headings
- Treatment Outcome
- STAT3 Transcription Factor
- STAT1 Transcription Factor
- Pyrroles
- Pyrimidines
- Pyrazoles
- Protein Kinase Inhibitors
- Piperidines
- Nitriles
- Male